17 Oct 2022, Nature Medicine
The eCLEAR study published their results in Nature Medicine in October.
This study combined the use of 3BNC117, which is a broadly neutralising antibody (bNAb), with a potent latency reversing agent, romidepsin, to reduce the HIV reservoir in individuals starting antiretroviral treatment (ART) for the first time.
The study was a phase II multicentre non-blinded randomised controlled trial (RCT) with eligible participants (n=60, 15 per arm) randomised 1:1:1:1 to one of four regimens:
a. ART alone
b. ART + romidepsin
c. ART + 3BNC117
d. ART + romidepsin + 3BNC117
The authors concluded that: “3BNC117 at ART initiation enhanced elimination of plasma viruses and infected cells, enhanced HIV-1-specific CD8+ immunity and was associated with sustained ART-free virologic control among persons with 3BNC117-sensitive virus.
These findings strongly support interventions administered at the time of ART initiation as a strategy to limit long-term HIV-1 persistence.”
The study sponsor was Aarhus University Hospital in Denmark with Professor Ole Schmeltz Søgaard as Chief Investigator. Aarhus Hospital is also in the process of opening as a recruiting site in RIO in 2023.